NIH, NCI budgets up by more than 5% in FY23; FDA gets more robust accelerated approval authority

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.

Trump administration and Cornell reach agreement to restore federal research funding

Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.

November 14, 2025

Vol.51 No.42

By Jacquelyn Cobb and Claire Marie Porter

Podcast

Site visits are gone, but outlook for new, centralized CCSG review is bright

One of the first things that happened as part of President Donald Trump’s “flooding of the zone” in January was the disappearance of the site visit as part of the Cancer Center Support Grant review.

November 05, 2025

NCI News Analysis

Cancer centers adapt to life without site visits as NIH changes CCSG review

Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Vinai GondiBridget KoontzPriya RastogiLisa LenrowNRG Oncology, an NCI National Clinical Trials Network group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple committees.

October 31, 2025

Vol.51 No.40

Podcast

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

NIH, NCI budgets up by more than 5% in FY23; FDA gets more robust accelerated approval authority

YOU MAY BE INTERESTED IN

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

Trump administration and Cornell reach agreement to restore federal research funding

Site visits are gone, but outlook for new, centralized CCSG review is bright

Cancer centers adapt to life without site visits as NIH changes CCSG review

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Early endpoints are a balance of risk and benefit

Renew today!

Subscriber content

Never miss an issue!

Login